Drug Database
Back to search

Netherlands· NL-e21e46deddba

Xcyst 500 mg, maagsapresistente tabletten

A methenamine product containing methenamine amygdalaat, registered in Netherlands by ACE Pharmaceuticals B.V.. The same ATC class is registered in 9 of our 19 countries.

ATC J01XX05

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedXcyst 500 mg, maagsapresistente table…ATCJ01XX05REGISTER NO.NL-e21e46deddbaPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about methenamine amygdalaatAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Methenamine is registered in 9 of 19 countries.

Countries holding a registration under ATC J01XX05 (methenamine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 4 of them publish a price we can compare per daily dose
Search methenamine products by name

Methenamine · ATC J01XX05

9 / 19 countries

  • Belgiumprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
METHENAMINE AMYGDALAAT
Manufacturer
ACE Pharmaceuticals B.V.
Country
Netherlands (NL)
ATC code
J01XX05
ATC class
Methenamine
Defined daily dose
2 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    04480

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

22 interactions on record for methenamine.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check methenamine against other medicinesHow interaction checks work

Methenamine · interactions on record

22 records

  • 4 severe
  • 18 moderate

Most severe, free to view

  • SulfasalazineA07EC01severe
  • SulfamethizoleB05CA04severe
  • SulfamethizoleJ01EB02severe
  • SulfasalazinM01CX02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Methenamine in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All methenamine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Germany · Antihydral, Methenamin Smartpractice Europe
  • Luxembourg · Antihydral
  • Poland · Pedipur

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/49b003c7-18e8-492c-b68f-d565551d9636
GET /v1/drugs/49b003c7-18e8-492c-b68f-d565551d9636?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Maagsapresistente tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h04480_smpc.pdf",
  "strength": null,
  "atc_label": "Methenamine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg04480",
  "excipients": [
    "COPOLYMEER VAN ETHYLACRYLAAT-METHACRYLZUUR (1:1)",
    "GLYCEROLTRIACETAAT (E 1518)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMLAURILSULFAAT",
    "NATRIUMWATERSTOFCARBONAAT (E 500 (II))",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "METHENAMINE AMYGDALAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h04480.pdf",
  "authorised_at": "1966/09/27",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "04480",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about methenamine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console